Leuprolide Acetate Powder for Injection 22.5 mg
1. WHAT IS IT?
Leuprolide Acetate 22.5 mg is a synthetic analogue of gonadotropin-releasing hormone (GnRH). This specific formulation is a very long-acting depot injection, typically administered once every 6 months (semi-annually). It comes as a sterile powder that must be reconstituted with a specific diluent just before intramuscular (IM) or subcutaneous (SC) injection by a healthcare professional. Its high dose and slow-release nature provide sustained suppression of sex hormones.
2. ADVANTAGES
- Maximum Convenience: The most significant advantage is its infrequent dosing schedule (once every 6 months), which is ideal for patients who require long-term hormonal suppression and prefer fewer clinic visits or injections. This greatly enhances patient adherence and reduces the burden of treatment.
- Consistent Hormone Suppression: Provides profound and very stable suppression of testosterone in men and estrogen in women over a prolonged period (6 months).
- Effective for Chronic Conditions: Particularly well-suited for chronic, hormone-dependent conditions where continuous hormone deprivation is necessary.
3. NATURE (Pharmacology and Mechanism of Action)
- Classification: It is a GnRH agonist.
- Mechanism of Action:
- Initial “Flare” Effect: Like other leuprolide formulations, initial administration leads to a temporary increase in GnRH receptor stimulation, causing a transient surge in LH and FSH, and consequently, a temporary rise in testosterone (in men) or estrogen (in women). This is known as the “flare” effect.
- Sustained Downregulation and Suppression: Continuous presence of high leuprolide levels desensitizes and downregulates the GnRH receptors in the pituitary gland. This effectively “shuts down” the pituitary’s ability to release LH and FSH.
- Profound Hormonal Blockade: The sustained suppression of LH and FSH leads to a significant and prolonged decrease in the production of sex hormones by the gonads. This achieves medical castration levels of testosterone in men and profoundly low estrogen levels in women. This hormonal deprivation is the therapeutic goal.
4. PRECAUTIONS
The precautions for the 22.5 mg dose are similar to other leuprolide formulations but are particularly important given the long duration of action:
- “Flare” Phenomenon: A temporary worsening of symptoms (e.g., increased bone pain, urinary obstruction in prostate cancer; increased pain in endometriosis) can occur during the first few weeks due to the initial hormone surge. This is crucial to anticipate and manage, especially in vulnerable patients (e.g., those with spinal cord compression from prostate cancer).
- Bone Mineral Density (BMD) Loss / Osteoporosis: Due to prolonged sex hormone deprivation, there is a significant risk of bone density loss, leading to osteoporosis and increased fracture risk. This is a major concern with long-term use. Calcium and Vitamin D supplementation, as well as regular BMD monitoring (DEXA scans), are highly recommended.
- Cardiovascular Risk: Men treated for prostate cancer, particularly those with pre-existing cardiovascular risk factors, may have an increased risk of heart attack, stroke, and sudden cardiac death. Close cardiovascular monitoring is advised.
- Metabolic Changes: Risk of developing or worsening diabetes and dyslipidemia (high cholesterol). Regular monitoring of blood glucose and lipid profiles is necessary.
- Mood Disturbances: Depression, including rare reports of suicidal ideation, has been reported. Patients and caregivers should be vigilant for mood changes and seek medical attention if they occur.
- Seizures: Caution is advised in patients with a history of seizures or risk factors for seizures.
- Pseudotumor Cerebri (PTC): Rare but serious condition characterized by increased pressure around the brain, causing severe headaches and vision problems.
- Pregnancy and Lactation: Absolutely contraindicated in pregnant or breastfeeding women. It can cause severe fetal harm. Women of reproductive potential must use effective non-hormonal contraception during treatment and for a prolonged period after the last injection (due to the 6-month release).
- Undiagnosed Abnormal Vaginal Bleeding: Should not be used in women with this condition until evaluated.
- Drug Interactions: Inform your doctor about all other medications, including over-the-counter drugs, supplements, and herbal products, as interactions can occur (e.g., with QT-prolonging drugs).
- Administration: Must be prepared and administered by a trained healthcare professional, ensuring proper reconstitution and injection technique.
5. STORAGE
- Unreconstituted Powder: Store at room temperature (typically 20°C to 25°C or 68°F to 77°F), in the original packaging to protect from light and moisture. Do not freeze.
- Reconstituted Solution: Once the powder is mixed with the diluent, the suspension must be injected immediately. It does not contain a preservative, and its stability rapidly degrades after reconstitution. Any unused portion must be discarded.
- Keep out of reach of children.